- Home
- STM vs ONC Comparison
STM vs ONC Comparison
Compare STM & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STM | ONC |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | Netherlands | Switzerland |
| Employees | 49602 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9B | 34.8B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | STM | ONC |
|---|---|---|
| Price | $33.48 | $317.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $34.25 | ★ $370.25 |
| AVG Volume (30 Days) | ★ 8.3M | 230.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.74 | $900.30 |
| Revenue Next Year | $11.17 | $21.97 |
| P/E Ratio | ★ $187.61 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.25 | $196.53 |
| 52 Week High | $35.07 | $385.22 |
Technical Indicators
Market Signals| Indicator | STM | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 59.48 | 35.71 |
| Support Level | $25.52 | $307.93 |
| Resistance Level | $35.07 | $350.56 |
| Average True Range (ATR) | 0.94 | 10.46 |
| MACD | -0.04 | -4.21 |
| Stochastic Oscillator | 47.75 | 6.49 |
Price Performance
Historical ComparisonAbout STM STMicroelectronics N.V.
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconducteurs in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeOne is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeOne runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeOne's revenue.